Puma Biotechnology Inc. (PBYI)

46.80
0.10 0.21
NASDAQ : Health Technology
Prev Close 46.70
Open 47.00
Day Low/High 46.33 / 47.10
52 Wk Low/High 40.45 / 136.90
Volume 90.85K
Avg Volume 894.50K
Exchange NASDAQ
Shares Outstanding 38.02M
Market Cap 1.80B
EPS -7.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

European Commission Grants Marketing Authorisation For Puma Biotechnology's NERLYNX® (neratinib) For Extended Adjuvant Treatment Of Hormone Receptor Positive HER2-Positive Early Stage Breast Cancer

European Commission Grants Marketing Authorisation For Puma Biotechnology's NERLYNX® (neratinib) For Extended Adjuvant Treatment Of Hormone Receptor Positive HER2-Positive Early Stage Breast Cancer

Puma Biotechnology, Inc. (Nasdaq:PBYI) announced that the European Commission (EC), has granted marketing authorisation for NERLYNX® (neratinib) for the extended adjuvant treatment of adult patients with early stage hormone receptor positive...

October 5th Options Now Available For Puma Biotechnology (PBYI)

October 5th Options Now Available For Puma Biotechnology (PBYI)

Investors in Puma Biotechnology Inc saw new options become available today, for the October 5th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PBYI options chain for the new October 5th contracts and identified one put and one call contract of particular interest.

Puma Biotechnology Reports Second Quarter 2018 Financial Results

Puma Biotechnology Reports Second Quarter 2018 Financial Results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2018.

September 28th Options Now Available For Puma Biotechnology (PBYI)

September 28th Options Now Available For Puma Biotechnology (PBYI)

Investors in Puma Biotechnology Inc saw new options begin trading today, for the September 28th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PBYI options chain for the new September 28th contracts and identified one put and one call contract of particular interest.

Puma Biotechnology Files New Drug Submission For NERLYNX® In Canada

Puma Biotechnology Files New Drug Submission For NERLYNX® In Canada

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Health Canada has accepted for review the Company's New Drug Submission (NDS) for the medicinal product NERLYNX® (neratinib) for the extended adjuvant treatment of adult...

Puma Biotechnology To Host Conference Call To Discuss Second Quarter Financial Results

Puma Biotechnology To Host Conference Call To Discuss Second Quarter Financial Results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.

Puma Biotechnology And Strata Oncology Announce Collaboration To Accelerate Enrollment In Neratinib HER2 Mutation Basket Study (SUMMIT Trial)

Puma Biotechnology And Strata Oncology Announce Collaboration To Accelerate Enrollment In Neratinib HER2 Mutation Basket Study (SUMMIT Trial)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, and Strata Oncology, Inc.

Puma Biotechnology Receives Positive CHMP Opinion Recommending Approval Of NERLYNX® For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer

Puma Biotechnology Receives Positive CHMP Opinion Recommending Approval Of NERLYNX® For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer

Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that on June 28, 2018 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorisation for the medicinal product NERLYNX® (neratinib) for the...

Puma Biotechnology Announces Results Of CHMP Reexamination Of MAA For Neratinib For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer

Puma Biotechnology Announces Results Of CHMP Reexamination Of MAA For Neratinib For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer

Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive trend vote recommending the approval of the Marketing Authorisation Application...

NSABP FB-10: Phase IB Dose-Escalation Study Evaluating The Combination Of Trastuzumab Emtansine (T-DM1) With Neratinib In Women With Metastatic HER2-Positive Breast Cancer (Graphic: Business Wire)

NSABP FB-10: Phase IB Dose-Escalation Study Evaluating The Combination Of Trastuzumab Emtansine (T-DM1) With Neratinib In Women With Metastatic HER2-Positive Breast Cancer (Graphic: Business Wire)

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that interim results from the Phase Ib/II FB-10 clinical trial of Puma's investigational drug PB272 (neratinib) given in combination with the antibody drug conjugate T-DM1...

Puma Biotechnology Reports First Quarter 2018 Financial Results

Puma Biotechnology Reports First Quarter 2018 Financial Results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2018.

Puma Biotechnology To Present At Bank Of America Merrill Lynch Health Care Conference 2018

Puma Biotechnology To Present At Bank Of America Merrill Lynch Health Care Conference 2018

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.

Puma Biotechnology To Host Conference Call To Discuss First Quarter Financial Results

Puma Biotechnology To Host Conference Call To Discuss First Quarter Financial Results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.

Puma Biotechnology And Pint Pharma Enter Into Exclusive Licensing Agreement To Commercialize NERLYNX® (neratinib) In Latin America

Puma Biotechnology And Pint Pharma Enter Into Exclusive Licensing Agreement To Commercialize NERLYNX® (neratinib) In Latin America

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and Pint Pharma International S.

NCCN Guidelines For Central Nervous System Cancers Include NERLYNX® (neratinib) In Combination With Capecitabine Or Paclitaxel As Treatment Options For Patients With Breast Cancer Brain Metastases

NCCN Guidelines For Central Nervous System Cancers Include NERLYNX® (neratinib) In Combination With Capecitabine Or Paclitaxel As Treatment Options For Patients With Breast Cancer Brain Metastases

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced today that NERLYNX® (neratinib) has been included as a recommended treatment option in the latest National Comprehensive Cancer Network...

Robbins Geller Rudman & Dowd LLP Announces Pending Class Action In The Puma Biotechnology, Inc. Litigation

Robbins Geller Rudman & Dowd LLP Announces Pending Class Action In The Puma Biotechnology, Inc. Litigation

The following statement is being issued by Robbins Geller Rudman & Dowd LLP regarding the Puma Biotechnology, Inc.

Home Depot, Vale, Bank of America: 'Mad Money' Lightning Round

Home Depot, Vale, Bank of America: 'Mad Money' Lightning Round

Jim Cramer focuses on Home Depot, Vale, Bank of America, Kraft Heinz, Dominion Energy, Lululemon Athletica, StitchFix, Duke Energy and more.

The Right Stuff: Cramer's 'Mad Money' Recap (Thursday 3/8/18)

The Right Stuff: Cramer's 'Mad Money' Recap (Thursday 3/8/18)

Jim Cramer says that on Thursday we saw the right stocks rally, even if we didn't see it in the averages. This market had breadth.

Puma Biotechnology To Present At Cowen's Annual Healthcare Conference

Puma Biotechnology To Present At Cowen's Annual Healthcare Conference

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.

Puma Biotechnology Reports Fourth Quarter And Full Year 2017 Financial Results

Puma Biotechnology Reports Fourth Quarter And Full Year 2017 Financial Results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2017.

Puma Biotechnology Receives Results Of CHMP Formal Decision For Neratinib For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer

Puma Biotechnology Receives Results Of CHMP Formal Decision For Neratinib For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer

Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion, recommending the refusal of the...

Puma Biotechnology To Host Conference Call To Discuss Fourth Quarter And Full Year Financial Results

Puma Biotechnology To Host Conference Call To Discuss Fourth Quarter And Full Year Financial Results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.

Puma Biotechnology To Present At LEERINK Partners Global Healthcare Conference

Puma Biotechnology To Present At LEERINK Partners Global Healthcare Conference

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.

Puma Biotechnology And CANbridge Life Sciences Enter Into Exclusive Licensing Agreement To Commercialize NERLYNX® (neratinib) In Greater China

Puma Biotechnology And CANbridge Life Sciences Enter Into Exclusive Licensing Agreement To Commercialize NERLYNX® (neratinib) In Greater China

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, have entered into an...

Puma Biotechnology Announces Publication Of Results From Phase II SUMMIT 'Basket' Trial Evaluating Neratinib In HER2 And HER3 Mutant Cancers

Puma Biotechnology Announces Publication Of Results From Phase II SUMMIT 'Basket' Trial Evaluating Neratinib In HER2 And HER3 Mutant Cancers

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that initial results from the company's ongoing SUMMIT Phase II 'basket' clinical trial of PB272 (neratinib) in patients with tumors harboring...

Puma Biotechnology And Medison Pharma Enter Into Exclusive Licensing Agreement To Commercialize NERLYNX® (neratinib) In Israel

Puma Biotechnology And Medison Pharma Enter Into Exclusive Licensing Agreement To Commercialize NERLYNX® (neratinib) In Israel

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and Medison Pharma Ltd, Israel's leading commercial partner for innovative pharmaceuticals, have entered into an exclusive agreement under which Medison...